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Abstract 
To determine the etiology of FDG uptake in vaginal tampons (VT), a known artifact in 
premenopausal women evaluated by PET/CT.  
Materials and Methods:  
This IRB approved study consisted of retrospective and prospective parts. The 
retrospective analysis included 685 women examined between January 2008 until 
December 2009 regarding VT presence. PET/CT images were analyzed to determine 
the localization and the standard uptake value (SUV) of VTs. We prospectively 
recruited 24 women (20 - 48 y.o.) referred for staging or follow-up in an oncology 
setting between February and April 2010, who were provided a commercial VT to be 
used during the entire examination after obtaining written informed consent. After 
image acquisition, VTs were individually analyzed for creatinine concentration and 
blood traces. Statistical significance was tested with the Mann-Whitney U test. 
Results:  
In the retrospective part, 38 of 685 women were found to have a VT of which 17 (45 
%) were FDG positive. A statistically significant correlation was found between FDG 
activity and VT position below the pubo-coccygeal line (PCL) (13 ± 11.2 mm). In the 
prospective study, 7 out of 24 (29 %) women had increased FDG activity in their VTs 
(SUV 18.8 ± 11 g/ml) but were not menstruating. FDG positive VTs were significantly 
lower in position (14.6 ± 11.4 mm, below PCL) than FDG negative VTs (p = 0.039). 
The creatinine concentration was significantly increased in all 7 positive VTs (931± 
615 µmol/l).  
Conclusion:  
FDG uptake in VTs is caused by urine contamination, which is likely related to 
localization below the PCL resulting in a contact with urine during voiding.  
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Introduction 
Increased 18F- Fluorodeoxyglucose (FDG) activity in vaginal tampons (VT) 
is a commonly encountered artifact in PET/CT [1-2]. Moderately increased FDG 
activity is observed frequently in the uterine cavity during menstrual bleeding [3-5], 
thus FDG activity in VTs due to menstrual blood is plausible.  However, in routine 
PET/CT, FDG activity in VTs is often in the range of brain or urine activity, rather than 
the blood pool, and localized mainly at the base of the VT. Although VTs are not 
expected to contain urine in case of proper intravaginal placement, we hypothesized 
that increased FDG uptake in VTs is caused by urine. Urine may reach the VT by 
capillary effect via its cotton string or its proximity to the voiding pathway.  
Although substantial FDG activity in a VT can be easily localized and 
identified in PET/CT examinations, high FDG uptake in VTs may obscure FDG 
activity of surrounding structures [6]. This has been described as a spill over artifact 
and occurs in the surroundings of high activity structures in PET and SPECT [7-8]. 
Therefore, especially in women with cervico-genital carcinoma this uptake should be 
prevented. To facilitate local staging of cervical cancer in MRI, several authors have 
proposed the use of VTs to distend the vaginal vault during imaging [9-10]. However, 
due to increased resolution of MRI imaging, the use of VTs is no longer 
recommended [11]. The use of VTs for local staging and follow-up of cervicogenital 
malignancy has not yet been reported for PET/CT, but in order to analyze a potential 
benefit of VTs for PET/CT examinations of cervicogenital malignancies, high FDG 
activities in the VT must be prevented. 
The aim of the present study was to determine whether FDG uptake in VTs 
is caused by menstrual blood, urine contamination or vaginal secretion, and to find a 
way to prevent it.  
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MATERIALS AND METHODS 
Patients 
This study was approved by the institutional review board of the hospital and 
consisted of a retrospective and a prospective part. In the retrospective part, 685 
PET/CT exams of women 20 - 48 y.o. scanned between 03.01.2008 and 30.12.2009 
were reviewed for VT presence and position in relation to the pubo-coccygeal line 
(PCL) as well as VT FDG activity. Medical charts were reviewed with particular 
attention to obstetric history. 
In the prospective part between February and April 2010, we recruited 
premenopausal women with known or suspected malignancies who regularly used 
VTs during menstruation and thus were familiar with their use. Exclusion criteria were 
cervical or genital carcinoma. To assess urine as a potential source of FDG activity in 
VTs, commercial VTs with normal cotton strings and modified VTs with non-
absorbable strings were examined in non-menstruating women. After having 
obtained written informed consent, medical history was taken on the day of 
examination, including last menstruation date and parity. 
 
PET/CT acquisition and analysis 
All women were examined using our standard protocol on a dedicated 
PET/CT scanner (GE Healthcare DISCOVERY ST 16 or DISCOVERY VCT 64, 7-8 
frames, frame time 1.5 or 2 minutes) with optional administration of 1 liter dilute oral 
contrast agent approximately 1 hour before the scan, injection of 350 - 370 MBq FDG 
40 - 45 minutes prior to the examination (approximate total dose equivalent for the 
entire PET/CT examination = 10 mSv), and voiding just before the examination to 
eliminate bladder activity [12].  
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In the retrospective analysis, PET/CT images were analyzed for maximum 
standard uptake value (SUVmax) of VTs. SUVmax (g/ml) was calculated by dividing 
the maximum FDG uptake (kBq/ml) by the injected dose (MBq) and multiplication 
with the lean body weight (kg). Furthermore, the distance from the base of the VT to 
the PCL was measured, with negative values indicating a position above and positive 
values indicating a position below the PCL (Fig. 1). 
 
In the prospective part, women were provided with a commercial VT (Ob® 
Regular, dimensions: 5 x 1.3 x 1.3 cm, Johnson & Johnson, NJ, USA) and asked to 
insert it. Every second VT was modified by replacing the cotton string with a sterile, 
non-absorbent nylon monofilament (Dermalon 3-0, Tyco Healthcare, USA). The 
investigators were blinded to string type. All patients were asked to insert the VTs 
before injection. After the FDG-uptake phase and prior to imaging, patients were 
asked to void with the VT in situ. PET/CT images then were analyzed for VT activity 
and position relative to the PCL.  
 
Analysis of the VT 
After completing imaging, all VTs were weighed and analyzed for FDG-
activity by use of an activity-meter. The change in weight was calculated by 
subtracting 2.9 g (average weight of unused Ob® Regular VTs). VTs were cut into 
equal thirds (base, middle and top), which were soaked separately for 3 - 4 hours in 
10 ml NaCl 9%. An aliquot of this sample was then evaluated for creatinine 
concentration using the Jaffe method [13]. 
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Statistical Analysis 
A SUVmax greater than 3 g/ml was defined as positive FDG uptake. 
SUVmax greater than 2.5 g/ml in soft tissue is considered to be abnormal [14]. 
However, due to the proximity to the highly active bladder, background uptake can be 
higher in the vaginal area. We therefore selected a cut off of 3 g/ml, to prevent false 
positive VTs. Statistic evaluation was undertaken by means of the non parametric 
Mann-Whitney U test for unpaired, non-normal distributed data, and the Pearson Chi-
Square test for binomial or categorical data (contingency tables), as appropriate. P 
values less than 0.05 were considered statistically significant (two-sided).  
 
RESULTS 
In the retrospective arm, VTs were found in 38 of 685 evaluated women, of 
which 17 (45 %) demonstrated increased FDG uptake. Patient details are listed in 
Table 1. Thirteen FDG positive VTs were located below the PCL (13 ± 11.2 mm), one 
7 mm above, and 3 VTs were just at the level of the PCL. In contrast, 12 of the FDG 
negative VTs were above and 9 slightly under the PCL (- 1.4 ± 6.9 mm) (Fig. 2a). A 
statistically significant positive correlation was found between positive FDG uptake 
and position below the PCL (p = 0.001).  
Twenty-four premenopausal women were included in the prospective study 
of which four were in the menstrual phase (patient details listed in Table 1). In seven 
patients (29%), VTs were FDG positive (SUVmax 18.8 ± 11.9 g/ml), none with blood 
traces evident at visual inspection. Five FDG positive VTs were localized below (20 ± 
7.5 mm), one at the level of, and one 3 mm above the PCL. In contrast, 9 of 17 
inactive VTs were at the level of or above the PCL (-6.6 ± 5.7 mm) and 8 inactive VTs 
were slightly below the PCL (6 ± 4.7 mm) (Fig. 2b). A statistically significant positive 
correlation was found between VT FDG uptake and position below the PCL (p = 
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0.039). Figure 3 is illustrating all 7 FDG active VTs of the prospective study and one 
FDG negative VT (Fig. 3a) for direct comparison. FDG activity was found at the base 
of all seven positive VTs, extending into the mid-portion in 2 cases (SUVmax 37.5 
g/ml, 23.7 g/ml; Fig. 3b and c) and into the superior portion in just one patient 
(SUVmax 24 g/ml, Fig. 3d). Of these seven positive VTs, six had the original 
manufacturer’s cotton string in place (SUVmax 15.7 ± 9.4 g/ml), while one was 
modified (i.e. cotton string replaced by nylon monofilament), with uptake at its base 
and middle portion (SUVmax 37.5 g/ml; Fig. 3c). Four of 24 women in the prospective 
study had blood traces on their VTs without increased FDG uptake. 
 
Pooling the retrospective and the prospective data resulted in a total of 62 
cases with FDG active VTs. Thirty-four VTs (54.8%) were located below the PCL, of 
which 18 (53%) showed increased FDG uptake. On the other hand, 17 VTs were 
located above the PCL, of which only 2 (11 %) were FDG positive. In the pooled 
data, no statistically significant correlation was found regarding VT FDG uptake and 
age (p = 0.169), body mass index (BMI) (p = 0.285) or height (p = 0.453) (Fig. 4). The 
obstetric history of 38 (61%) patients was known. No statistically significant 
correlation was found for parity and VT FDG uptake (p = 0.350, Pearson Chi 
Square). Table 2 shows the distribution of FDG positive and negative VTs.  
In the prospective arm, activity in the VTs after removal ranged from 202 to 
919 kBq, with an average of 518 ± 308 kBq. Creatinine concentration was increased 
in all seven FDG positive VTs, which was consistently found at the base, and to a 
lesser degree  in the mid and superior portions (base: 728 ± 871 µmol/l, middle: 469 
± 595 µmol/l, top (positive only for 5 out of 7 VTs): 216 ± 149 µmol/l). In contrast, in 
none of the three FDG negative VTs, which served as negative controls, were 
creatinine concentrations within detectable limits (< 18 µmol/l).  A high correlation 
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was noted between SUVmax and VT creatinine concentration (p < 0.001, R2= 0.772, 
y = 0.016 x + 2.842) (Fig. 5a). Active VTs showed a significantly greater increase in 
weight after use (3.416 ± 2.478 g, range 1.35 g - 8.5 g) compared to FDG negative 
VTs (0.501± 0.311 g, range 0.026 - 1.032 g; p < 0.001) (Fig. 5b). Calculating with a 
specific gravity of 1 g/ml for urine, and subtracting 0.5 g for vaginal secretion (i.e. 
average increase in weight of FDG negative VTs), the average absorbed urinary 
volume is estimated at 2.8 – 2.9 ml, with a maximum of 7.97 ml.   
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DISCUSSION 
This study provides strong evidence that urinary contamination is the 
cause of FDG positive vaginal tampons (VT) in PET/CT scanning. Particularly, in 
non-menstruating women, creatinine concentration and FDG uptake in VTs 
correlated well with the increase in weight of up to 8.5 g, proving the presence of 
urine in VT. In addition, the local distribution of creatinine mainly at the base with 
lower concentration in the middle or top of the VT correlated well with the imaging 
findings, which always showed FDG accumulation at the base. While urinary 
contamination of VTs is not a priori expected, the increased FDG uptake in VTs 
cannot be explained by menstrual blood, because of dominant radioactivity in the 
caudal portions of the VTs and because seven non-menstruating women also had 
FDG positive VTs. If vaginal secretion of FDG or F-active metabolites were causative 
for VT activity, one would first expect an equal activity distribution over the whole 
surface of the VTs and therefore also in their top portions. Second, FDG activity 
would be expected to be increased in the vaginal lumen even in patients without VTs. 
Third, vaginal secretion has an average glucose concentration of approximately 5.0 
mM, which is in the range of typical fasting blood sugar levels. Hence, VT FDG 
concentration in vaginal secretion should not be higher than blood pool values (SUV 
1.5 – 2.5 g/ml) [15]. 
 
The prevalence of involuntary leakage of urine for premenopausal women 
at the age of 20 – 44 is 9-23% and is mainly due to stress urinary incontinence [16]. 
Involuntary leakage in premenopausal women during the uptake phase in a resting 
supine position without physical activity is unlikely. Therefore contamination of the VT 
is likely to occur during voiding, either by direct contamination due to VT positioning 
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facilitating its contact with urine or by capillary action of the VT string positioned in the 
voiding pathway. 
Direct contamination can only occur when at least a part of the VT is in the 
voiding pathway. A good correlation was seen between FDG uptake and position of 
the VT base at or below the pubo-coccygeal line (PCL). Therefore, such a caudal 
position seems to be a risk factor for direct urinary contamination. Possible 
explanations for a low VT position could be poor placement of the VT or a weakness 
of the pelvic floor, and therefore related to age or parity. However, we could not show 
such correlations in our premenopausal collective.   
A contributory factor of capillary action by the cotton string is questionable. 
The observations in the prospective group suggest that a modified string could 
reduce contamination since only one modified and six normal VT showed increased 
activity. However, sheer capillary action of the cotton strings cannot explain quantities 
of VT urine content of up to 8 ml.  
Very intense FDG activity can obscure adjacent structures due to the so 
called “blooming” or “spill over” artifact [6-8]. Especially in women with cervicogenital 
malignancies such artefacts could impair diagnostic accuracy. In addition, also the 
incidental finding of pathological activity in the cervical region could be obscured by a 
highly FDG avid VT. Therefore all possible measures should be taken to avoid FDG 
uptake in VTs. As a consequence of the evidence that urinary contamination during 
voiding is the reason for FDG accumulation in VTs, we suggest three options to 
prevent this uptake. First, the VT has to be replaced immediately before PET/CT and 
after voiding. Secondly, the VT has to be removed prior to PET/CT, or thirdly VTs will 
have to be designed differently.   
The fact that urine can be found in 39% of the VTs after voiding raises also 
concerns for the general female population, using VTs. What impact this urine 
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contamination can have on comfort and hygiene, however, cannot be answered with 
the present study and needs further investigations.    
 
A limitation of this study is the incomplete obstetric and gynecologic history 
for the patients in the retrospective study, in particular, regarding the regular use of 
VTs and parity. This study cannot differentiate between different factors which may 
contribute to low VT position, such as improper VT insertion, caudal migration in a 
resting state or during voiding, or pelvic floor weakness. Therefore further 
investigations regarding VT position and the voiding dynamics of the pelvic floor 
would be needed. 
 
In conclusion, frequently observed FDG uptake in VTs is not caused by 
menstrual blood, but is due to urinary contamination which is related to VT position 
below the pubo-coccygeal line leading to direct contact with the voiding pathway.  
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TABLES  
Table 1 
Patient demographics 
 Retrospective Prospective p 
Number of patients 38 24 - 
Age (years  SD) 36  8.4 38  8.5 0.175 
Menstrual bleeding n.a. 4 (16.6%) - 
Body mass index (kg/m
2
 SD) 23.7  4.9 22.5  4.8 0.731 
Parity 0.7  1 0.6  0.84 0.664 
Primary tumor 
        Breast cancer 
        GIST  
        Melanoma 
        Colon carcinoma 
        Lymphoma 
        Focal nodular hyperplasia 
        Bronchial carcinoma 
        Thyroid carcinoma 
        Osteosarcoma 
        Ewing sarcoma 
        Pharyngeal carcinoma 
        Infection 
 
13 
1 
10 
2 
6 
0 
0 
1 
1 
1 
1 
2 
 
7 
1 
6 
2 
4 
1 
2 
1 
0 
0 
0 
0 
 
 SD = standard deviation 
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Table 2  
Previous vaginal delivery versus FDG-activity in VTs 
     
Parity 0 Parity ≥ 1 Total 
No FDG-activity in VTs 
13 7 20 
FDG-activity in VTs 
9 9 18 
Total 
22 16 38 
P = 0.350 (Pearson Chi-Square test) 
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FIGURES 
 
Fig. 1 Sagital FDG-PET/CT trough the pelvis demonstrating the analysis of the VT 
position in a 37 y.o. woman with breast cancer. The perpendicular distance (x) from 
the base of the VT to the PCL (bold white line) was determined, with negative values 
denoting VT position above and positive values denoting VT position below the PCL. 
U = Uterus, C = cervix, B = bladder, filled with urine with a high FDG activity. 
 
Fig. 2 PET/CT data analysis – Correlation between VT position and FDG activity, 
illustrated with box plots for FDG negative vs positive VTs. a) In the retrospective 
study (n= 38) for VT position above (negative) or below the PCL (mm) (p = 0.001, 
Man-Whitney U test) and b) analogous in the prospective part (p = 0.039, Man-
Whitney U test).  
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Fig. 3 Sagital fused PET/CT images through the pelvis of 8 non-menstruating women 
in the prospective study: a) VT Position relative to the PCL in a patient with an FDG 
negative VT (*), with its base located at the level of the PCL (white line), creatinine 
concentration was not measurable. b-h) All 7 FDG positive VTs of the prospective 
study have a high creatinine concentration, mainly at the base (728 ± 871 µmol/l). b-
f)  Five VT were located clearly below the PCL, g) one just at the level of the PCL, 
and h) one 3 mm above the PCL.  
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Fig. 4 Box plots for correlation of FDG activity in VTs with Age, BMI or Height: 
Statistical comparison with the Man-Whitney U test for FDG negative vs positive VTs 
in the pooled data (N= 62): a) for age (p = 0.169), b) body mass index (BMI) (p = 
0.903) and c) for height (p = 0.453). No correlation was found. 
 
 
Fig. 5 Results of the VT analysis regarding creatinine concentration and weight: a) 
Correlation between FDG-uptake and creatinine concentration in 10 VTs. All seven 
VTs with increased FDG-uptake (SUV > 3 g/ml), had increased creatinine 
concentrations which correlated well with FDG-uptake / SUVmax. Three VTs with an 
SUV < 3 g/ml served as negative controls and were not found to have creatinine 
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concentration within detectable limits (< 18 mol/l); b) Box plot graph illustrating 
weight increases after use for all patients without menses, with no overlap between 
FDG negative and FDG positive VTs and a significant correlation between increased 
weight and activity (p < 0.001).  
 
 
 
 
 
 
 
